Type 2 Diabetes in Youth

Goutham Rao, MD¹ and Elizabeth T. Jensen, PhD²

Abstract

The incidence of type 2 diabetes in children and adolescents in the United States rose at an annual rate of 4.8% between 2002-2003 and 2014-2015. Type 2 diabetes progresses more aggressively to complications than type 1 diabetes. For example, in one large epidemiological study, proliferative retinopathy affected 5.6% and 9.1% of children with type 1 and type 2 diabetes, respectively. Screening begins at age 10 or at onset of puberty, and is recommended among children with a BMI% ≥85 with risk factors such as a family history and belonging to a high risk racial or ethnic or racial group. HbA1C% is preferred for screening as it does not require fasting. As distinguishing between type 1 and type 2 diabetes is not straightforward, all children with new onset disease should undergo autoantibody testing. Results of lifestyle interventions for control of type 2 diabetes have been disappointing, but are still recommended for their educational value and the potential impact upon some participants. There is limited evidence for the benefit of newer medications. Liraglutide, a GLP-1 agonist, however, has been shown to significantly reduce HbA1C% in one study and is now approved for children. Liraglutide should be considered as second line therapy.

Keywords

type 2 diabetes children adolescents

What do we already know about this topic?
We have known that the incidence and prevalence of type 2 diabetes in children and adolescents is steadily rising.

How does your research contribute to this field?
We provide an overview useful to clinicians which describes the epidemiology, diagnosis, prognosis, and treatment of type 2 diabetes, with an emphasis upon studies published in the past 5 years.

What are your research’s implications toward theory, practice, or policy?
We believe more studies on newer type 2 diabetes agents are needed, to improve its prognosis in children and adolescents and the quality of life among those affected.

Introduction

The rising worldwide prevalence of childhood obesity is well known.¹ Roughly 18.5% of American children and adolescents had obesity in 2016 compared to 14.6% in 1999.² The problem also affects children in less developed countries. Data from 45 countries in Africa, for example, reveals an obesity prevalence of 6.9%.³ Less well known is the related parallel increase in the incidence and prevalence of type 2 diabetes. Obesity increases the risk of incidence of type 2 diabetes in children and adolescents more than 4-fold.⁴ Children from non-European backgrounds are severely affected. Among American Indian/Alaskan Native children 29.7% of whom have obesity,⁵ for example, type 2 diabetes makes up 80% of all diabetes cases.⁶ Affected children are more likely to suffer complications than children with type 1 diabetes.⁷ Despite the magnitude of the problem, the problem remains unfamiliar to many clinicians. In one survey, albeit from 2003, just 15.3% of pediatricians felt well-prepared to manage type 2 diabetes.⁸ Furthermore, significant gaps exist in our overall understanding of the epidemiology, prognosis, and treatment of type 2 diabetes in...
youth. Our goal was to summarize the most recently available epidemiological data, and to provide recommendations for diagnosis and treatment based on recent guidelines and studies. We reviewed available data from the SEARCH for Diabetes in Youth (SEARCH) and Treatment Options for Type 2 Diabetes in Adolescents in Youth (TODAY) study, as well as other relevant published reports included in the PubMed database from 2015 to 2020. Data comes primarily from the United States, but our recommendations are broadly applicable.

Epidemiology

Epidemiological data comes primarily from SEARCH, a population-based, American registry and cohort study of youth onset (<20 years of age) diabetes of all types. Since 2001, incident and prevalent cases of youth-onset diabetes have been recorded across 4 geographical areas in the US including Native American reservations.6,9 Type 2 diabetes incidence and prevalence estimates are restricted to youth 10 to 19 years of age, due to few cases <10 years of age.10

Prevalence is estimated every 8 years. In 2009 there were 46 cases of type 2 diabetes/100 000 youth (95% CI 31/100 000, 37/100 000).11 American Indians had the highest prevalence (120 cases/100 000). Prevalence was lowest among non-Hispanic whites (17 cases/100 000) (Table 1). With the exception of American Indian and Asian Pacific Islander youth, the prevalence increased across all age, sex and racial and ethnic groups between 2001 and 2009, with an overall increase of 30.5%. Prevalence estimates for 2017 are still being calculated.

As opposed to prevalence, more recent incidence estimates are available. The 2014-2015 incidence was 13.8 cases/100 000. Incidence was higher in girls (16.7 cases/100 000) than boys (11.1 cases/100 000) and among older (ages 15-19 years (15.2/100 000)) versus younger (10-14 years (12.4/100 000)) participants. From 2002-2003 to 2014-2015, after adjusting for demographic changes, there was a 4.8% annual percent increase in incidence (Table 1).7

What Have We Learned About Prognosis?

Our understanding of long term consequences is limited. Most evidence indicates that type 2 diabetes progresses aggressively. Relative to type 1 diabetes diagnosed in adolescence, children with type 2 diabetes are more likely to develop ≥1 complications as teens or young adults (72% vs 32%).12 Specific complications are discussed below.

Peripheral Neuropathy

In SEARCH, 22% of participants with type 2 diabetes had evidence of clinical peripheral neuropathy13 and 34% had evidence of subclinical diabetic peripheral neuropathy.14 Male sex, smoking, lower HDL, and longer illness duration increased risk.10

Kidney Disease

In SEARCH, kidney disease affected 19.9% of type 2 diabetes participants, comparable to the prevalence of

| Demographic characteristic         | Prevalence 2009 cases/100 000 (95% CI) | Incidence 2015 cases/100 000 (95% CI) | Incidence change 2002-2015 APC (95% CI)* |
|------------------------------------|----------------------------------------|----------------------------------------|------------------------------------------|
| Overall                            | 46 (43-49)                             | 13.8 (12.4-15.3)                       | 4.8 (3.7-5.9)                            |
| Age at diagnosis                   |                                        |                                        |                                          |
| 10-14                              | 23 (20-26)                             | 12.4 (10.6-14.5)                       | 4.6 (3.0-6.2)                            |
| 15-19                              | 68 (63-74)                             | 15.2 (13.2-17.5)                       | 5.0 (3.5-6.6)                            |
| Sex                                |                                        |                                        |                                          |
| Female                             | 58 (53-63)                             | 16.7 (14.6-19.1)                       | 5.1 (3.6-6.6)                            |
| Male                               | 35 (31-39)                             | 11.1 (9.4-13.0)                        | 4.4 (2.7-6.2)                            |
| Race/ethnicity                     |                                        |                                        |                                          |
| Non-Hispanic white                 | 17 (15-20)                             | 4.5 (3.5-5.7)                          | 0.8 (−1.4-2.9)                          |
| Non-Hispanic black                 | 106 (93-122)                           | 37.8 (31.9-44.7)                       | 6.0 (4.1-7.9)                           |
| Hispanic                           | 79 (70-88)                             | 20.9 (17.4-24.9)                       | 6.5 (4.4-8.5)                           |
| Asian/Pacific Islander             | 34 (26-46)                             | 11.9 (7.8-18.3)                        | 7.7 (3.4-12.2)                          |
| American Indian                    | 120 (96-151)                           | 32.8 (20.8-51.6)                       | 3.7 (0.1-7.4)                           |

*Adjusted annual percent change—adjusted for change in demographic distribution across surveillance period.
18% identified in the TODAY Study (see below for description). Albuminuria progresses more rapidly among children with type 2 compared to type 1 diabetes. Risk factors for progression include poor glycemic control, lack of private insurance, African American race, and lower insulin sensitivity.

Retinopathy

In one pilot SEARCH study, the prevalence of any retinopathy was 42% among those with type 2 diabetes compared with 17% among those with type 1 diabetes. In a larger SEARCH study, proliferative retinopathy was found among 9.1% of type 2 versus 5.6% of type 1 children with diabetes within just 5 to 10 years of diagnosis—once again substantiating the relative aggressiveness of type 2 diabetes. Retinopathy was present in 13.9% of TODAY participants at the end of the study.

Cardiovascular Risks

Criteria for metabolic syndrome include hypertension, HDL cholesterol ≤ 1.0 mmol/L (40 mg/dL), triglycerides ≥ 2.8 mmol/L (110 mg/dL), and waist circumference > 97th percentile. In SEARCH, among youth with type 2 diabetes, at a mean participant age of 15.5 years, and mean disease duration of 2.6 years, 31.7% met criteria for metabolic syndrome. This is comparable to the prevalence of metabolic syndrome among all children with obesity. Arterial stiffness, a marker of vascular damage prognostic for atherosclerosis, was detected in 47.4% of SEARCH participants (mean age 22 years at assessment) and 50% of TODAY study participants. Autonomic dysfunction of the cardiovascular system (CAN) is a significant risk factor for cardiovascular morbidity. CAN is diagnosed based on an abnormal response to a series of cardiovascular autonomic reflex tests. CAN affects roughly 20% of adults with diabetes and is associated with a 5-fold increase in mortality.

In SEARCH, among participants with a mean (SD) disease duration of 8 (± 2) years, 17% met criteria for CAN. Risk factors included elevated triglycerides and albuminuria.

Mortality

Through linkage of SEARCH and the U.S. National Death Index data through 2010, and among type 2 diabetes participants diagnosed from 2002 to 2008, the mortality rate was 185.6 deaths/100,000 person-years as compared to an expected mortality rate of 70.9 deaths/100,000 person-years. The age, sex, and race-standardized mortality ratio was 2.4 (95% CI: 1.3-3.9) for type 2 diabetes participants. By contrast, no increase in mortality was observed for type 1 participants.

Diagnosis

Screening and Diagnostic Criteria

Criteria are nearly uniform among different international guidelines. Screening begins at age 10 or at puberty if it occurs earlier and should be based on the presence of risk factors, which include overweight or obesity (BMI ≥ 85th percentile) plus ≥ 1 additional risks. Additional risks include: maternal gestational diabetes; a family history of type 2 diabetes (first or second degree relative); belonging to a specific race or ethnicity. In the US, these include Native American, African American, Latino, Asian American, and Pacific Islander; and signs of insulin resistance and associated metabolic conditions including acanthosis nigricans, hypertension, dyslipidemia, polycystic ovaries syndrome (PCOS) or small for gestational age birth weight. Screening should be repeated every 3 years, or more frequently if BMI is increasing rapidly. A diagnosis can be made based upon fasting plasma glucose, the 2-hour oral glucose tolerance test, HbA1C% level, or random glucose in the presence of typical diabetes symptoms. Diagnostic criteria are well established and are summarized in Table 2. These are based on adult criteria and have not been validated in children. The usefulness of HbA1C% level, in particular, has come under a great deal of scrutiny. Several studies have shown poor sensitivity when compared to the oral glucose tolerance test (OGTT). By contrast, Chan et al reported that both OGTT and HbA1C% predict free-living glycemia equally well. No long-term studies have demonstrated the correlation between HbA1C% in children and diabetes outcomes. However, this is also true for the other tests. All things considered, as studies confirming the long-term validity of diagnostic criteria are unlikely to emerge in the near future, we believe clinicians should rely on recommended criteria. As HbA1C% does not require fasting, it is often easier to perform in children and has been associated with higher screening rates.

Distinguishing Between Type 1 and Type 2 Diabetes

Distinguishing between type 1 and type 2 diabetes in children can be challenging. The classic type 1
diabetes phenotype of a thin child who presents with diabetic ketoacidosis (DKA) is valid, but many children with type 1 diabetes also have overweight or obesity. Also, roughly 11% of children with type 2 diabetes present with DKA.\textsuperscript{37} The presence of specific autoantibodies including islet antigen-2 antibody (IA-2), glutamic acid decarboxylase-65 antibody (GAD65), and insulin autoantibody (IAA), which indicate the pancreatic B-cell destruction, can be useful in distinguishing diabetes type.\textsuperscript{38} Even here, many children with a clinical phenotype consistent with type 2 diabetes have autoantibodies. For example, among 1206 children initially assessed for enrollment in the TODAY study, 9.8% were antibody positive. These children were, however, less likely to be obese and more likely to require insulin sooner and therefore bore more resemblance to typical children with type 1 diabetes.\textsuperscript{39} For these reasons, it is recommended that autoantibody testing be considered in all children with a new diagnosis of diabetes, with one or more positive antibody test strongly indicative of type 1 diabetes or antibody-positive type 2 diabetes.\textsuperscript{6} A reasonable autoantibody testing panel includes GAD65 with at least one of IA-2, IAA, islet cell cytoplasmic antibody IGG, (ICA), or zinc transporter 8 antibody (ZnT8).\textsuperscript{40}

**Monogenic Diabetes**

Though rare, clinicians should be familiar with monogenic diabetes which is in the differential diagnosis of type 2 diabetes. Unlike type 1 and type 2 diabetes, monogenic diabetes is inherited in an autosomal dominant fashion. It includes neonatal diabetes and different forms associated with mutations in 14 genes known as maturity-onset diabetes of the young (MODY). MODY is often misdiagnosed as type 1 or type 2 diabetes. It represents approximately 1.2% of cases of pediatric diabetes.\textsuperscript{41} Neonatal diabetes represents an additional 0.2% of cases.\textsuperscript{42} Most individuals with MODY are non-obese, diagnosed before age 25, and have a parent with MODY.\textsuperscript{43} Pancreatic autoantibodies are absent and C-peptide is detectable 3 to 5 years after diagnosis.\textsuperscript{44} Next generation genetic testing should be considered under such circumstances. Treatment depends upon MODY subtype. For example, glucokinase-maturity-onset diabetes of the young (GCK-MODY) is characterized by only mild hyperglycemia requiring no treatment. By contrast, the most common type, hepatocyte nuclear transcription factor 1A-maturity-onset diabetes of the young (HNF1A-MODY) is characterized by insulin secretory defects, and microvascular complications are strongly related to glycemic control.\textsuperscript{45} Further details about monogenic diabetes are beyond the scope of this review.

**Treatment**

**Lifestyle Approaches**

Among newly diagnosed children, lifestyle management is the recommended initial approach.\textsuperscript{20,21} This should include encouragement of healthy eating, 30 to 60 minutes of moderate or vigorous physical activity ≥5 days/week, and strength training ≥3 days/week. Also recommended is comprehensive diabetes education and self-management support. Unfortunately, the likelihood of successful control through lifestyle intervention is low. Even among adults in one large study, only 3.5% were able to achieve diabetes remission through an intensive lifestyle-based intervention after 4 years.\textsuperscript{46} A large proportion of youth with type 2 diabetes fail to achieve a healthier weight or improved control.\textsuperscript{47} Adherence by children in non-research settings is a significant issue. In a study of non-Hispanic black youth in New York with type 2 diabetes, 39% dropped out of medical care within 2 years, and 78% within 5 years.\textsuperscript{48}

**Lessons From TODAY and Other Studies**

The TODAY study was a multiethnic, multicenter randomized trial which compared 3 treatment approaches in obese children age 10 to 17 with type 2 diabetes: metformin alone; metformin plus the thiazolidinedione rosiglitazone; and metformin plus an intensive lifestyle intervention.\textsuperscript{39} The TODAY lifestyle program (TLP) was designed to promote a weight loss of 7% to 10% of initial weight through counseling.\textsuperscript{50} The primary...
outcome was treatment failure, defined as a persistently elevated HbA1C% ≥8%. Rates of failure were 51.7%, 38.6%, and 46.6% for metformin alone, metformin plus rosiglitazone, and metformin plus TLP, respectively, with no statistically significant difference between metformin alone and metformin and TLP. A decrease of at least 7 percentage points in percent overweight for individual enrollees was considered to be clinically meaningful. This degree of reduction after 6 months was achieved in 31.2% in the metformin plus TLP group, 16.7% in the metformin plus rosiglitazone group, and 24.3% in the metformin alone group. The difference between the metformin and metformin plus TLP groups was not statistically significant.

The discouraging impact of lifestyle changes in the TODAY study is echoed by the huge number of published studies of treatments for overweight and obesity in general. In a comprehensive overview of 6 Cochrane systematic reviews, Ells et al reported that multi-faceted behavior change programs can have at best a modest impact upon weight status in children and that overall reports of effectiveness show no improvement since 2009. However, we still support recommending lifestyle changes. First, lifestyle management programs do not generally have adverse effects. Second, even if participation and engagement is poor by youth and families, they are still likely to receive some useful information about what changes are beneficial. Finally, type 2 diabetes has an enormous impact upon a child’s current and future health. It is hard to predict which children will benefit significantly from a lifestyle management program. A highly positive impact on a small number of children can be viewed as a success, even if the majority of children do not achieve improved outcomes. We do advise clinicians to be realistic about the success of lifestyle management, and to recognize that many children will require pharmacotherapy.

**Newer Pharmacotherapies**

The newer classes of diabetes medications include glucagon-like peptide 1 (GLP-1) agonists, dipeptyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Newer agents have revolutionized adult diabetes care. The SGLT2 inhibitors, for example, have been shown not only to control diabetes, but also to improve renal and cardiovascular outcomes. Newer agents were not available at the time of the TODAY study, nor are they explicitly recommended in current guidelines. The evidence base is, however, growing.

GLP-1 agonists improve glucose control through enhanced insulin secretion, suppression of glucagon secretion, and delaying gastric emptying. They also promote weight loss. In 2019, the results of a trial comparing the GLP-1 agonist liraglutide plus metformin to placebo plus metformin among 134 children with type 2 diabetes who were receiving metformin with or without insulin, were published (Ellipse trial). After 26 weeks, HbA1C% declined by 0.64 points in the liraglutide arm compared with an increase of 0.42 points in the placebo arm (difference of −1.06, 95% CI, −1.65 to −0.46). Moreover, in June 2019, liraglutide became the first GLP-1 agonist approved for type 2 diabetes treatment in children and the first non-insulin treatment approved for children since metformin was approved in 2000. It is administered daily subcutaneously which may limit acceptability. Gastrointestinal side effects are common. It is very expensive (retail cost >$1100 per month). An oral form of the GLP-1 agonist, semaglutide, has recently become available but has not been studied in children. Studies of other newer agents are very limited in number and include primarily only pharmacokinetic/pharmacodynamic and safety outcomes. Based on a search of ClinicalTrials.gov, Table 3 summarizes 3 clinical trials of newer agents with outcomes (including the Ellipse trial).

Given the aggressiveness of type 2 diabetes and the promising results with liraglutide and other agents, we believe strongly that newer agents should be considered as second-line treatment after metformin and prior to or along with insulin. We also believe that more GLP-1 agonists, DPP-4 inhibitors, and SGLT-2 inhibitors will be approved for use in children, transforming care for type 2 diabetes just as they have among adults.

**Research Gaps**

Type 2 diabetes appears to follow a more aggressive course than type 1 diabetes in youth. Many questions remain, however, about the long term impact. For example, it is unknown how early onset type 2 diabetes affects reproductive health and the health of offspring.

Lifestyle approaches to management of type 2 diabetes have so far proven disappointing. New strategies are needed to engage children and families in sustainable lifestyle changes for better control and to slow disease progression. As non-European children are at high risk, new culturally sensitive approaches which take into account dietary and taste preferences, eating patterns and other factors are essential.

Finally, the options available for pharmacological treatment of type 2 diabetes in youth are expected to increase rapidly in the coming years. There is a need for studies of additional GLP-1 agents, SGLT-2 inhibitors, and DPP-4 inhibitors in youth with type 2 diabetes.
Table 3. Studies of Newer Agents for Type 2 Diabetes in Children.

| Agent          | Dosage                              | Class               | Enrollees                                      | Comparison | Principal outcome(s)                                                                 | Adverse effects                                                                 |
|----------------|-------------------------------------|---------------------|------------------------------------------------|------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Liraglutide    | Up to 1.8 mg daily                  | GLP-1 agonist       | 135 children age 10-17 with HbA1C% of 6.5-11.0, treated with metformin | Placebo    | HbA1C% declined 0.64 in liraglutide group; increased by 0.42 in placebo arm after 26 weeks. (Difference, −1.06, 95% CI, −1.65 to −0.46) | Nausea and vomiting. Relative risk of nausea of 2.18, 95% CI, 1.06, 4.46 and vomiting 2.92, 95% CI, 1.23, 6.95 compared to placebo over 52 weeks trial period. |
| Saxagliptin    | 2.5 mg or 5.0 mg daily depending upon body weight | DPP-4 inhibitor | 26 children age 10-17 with HbA1C% ≥ 7.0 ≤ 10.5. Results for only 8 children analyzed. | Placebo    | HbA1C% declined by mean of 0.83 in saxagliptin group and increased by 0.6 in placebo group after 16 weeks. | Pneumonia in one child treated with saxagliptin. |
| Saxagliptin    | 1.5 mg or 5.0 mg daily depending upon body weight | DPP-4 inhibitor | 32 children age 10-17 with HbA1C% ≥ 7.0 ≤ 10.5. Results for only 6 children analyzed. | Saxagliptin + metformin IR/XR 1000-2000 mg daily; Placebo + metformin IR/XR 1000-2000 mg daily. | HbA1C% declined by mean of 1.0 in saxagliptin group and increased by 0.9 in placebo group after 16 weeks. | 2/4 children in saxagliptin group experienced headache compared with zero in placebo group. |

**Notes:**
- Liraglutide: Clinicaltrials.gov. Bethesda (MD). National Library of Medicine. Identifier NCT01204775. Study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of saxagliptin as monotherapy in pediatric patients with type 2 diabetes. April 18, 2017. Cited January 1, 2020. https://www.clinicaltrials.gov/ct2/show/study/NCT01204775?term=pediatric+type+2+diabetes&cond=saxagliptin&draw=2&rank=1
- Saxagliptin: Clinicaltrials.gov. Bethesda (MD). National Library of Medicine. Identifier NCT01434186. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of saxagliptin (BMS-477118) in combination with metformin IR or metformin XR in pediatric patients with type 2 diabetes who have inadequate glycemic control on metformin alone. April 18, 2017. Cited January 1, 2020. https://www.clinicaltrials.gov/ct2/show/results/NCT01434186?term=bms-477118&draw=2&rank=2
Author Contributions

GR and ETJ contributed equally to the conception, design, analysis and interpretation of data, drafting, and revising of this review article. Both authors approved the final version to be published.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Goutham Rao https://orcid.org/0000-0001-7739-9353

References

1. Anderson PM, Butcher KF, Schanzenbach DW. Understanding recent trends in childhood obesity in the United States. Econ Hum Biol. 2019;34:16-25.
2. Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999-2016 [published correction appears in Pediatrics. 2018 Sep;142(3)]. Pediatrics. 2018;141:e20173459.
3. Adom T, Kengne AP, De Villiers A, Puoane T. Prevalence of overweight and obesity among African primary school learners: a systematic review and meta-analysis. Obes Sci Pract. 2019;5:487-502.
4. Abbasi A, Juszczyk D, van Jaarsveld CHM, Gulliford MC. Body mass index and incident type 1 and type 2 diabetes in children and young adults: a retrospective cohort study. J Endocr Soc. 2017;1:524-537.
5. Bullock A, Sheff K, Moore K, Manson S. Obesity and overweight in American Indian and Alaska Native children, 2006-2015. Am J Public Health. 2017;107:1502-1507.
6. SEARCH for Diabetes in Youth Study Group, Pettitt DJ, Talton J, Dabelea D, et al. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care. 2014;37:402-408.
7. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26:2999-3005.
8. Ditmyer MM, Price JH, Teljohann SK, Rogalski F. Pediatricians’ perceptions and practices regarding prevention and treatment of type 2 diabetes mellitus in children and adolescents. Arch Pediatr Adolesc Med. 2003;157:913-918.
9. SEARCH for Diabetes in Youth Study Group, Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37:3336-3344.
10. Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in incidence of type 1 and type 2 diabetes among youths — selected counties and Indian reservations, United States, 2002–2015. MMWR Morb Mortal Wkly Rep. 2020;69:161-165.
11. SEARCH for Diabetes in Youth Study Group, Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778-1786.
12. SEARCH for Diabetes in Youth Study Group, Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317:825-835.
13. Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care. 2017;40:1226-1232.
14. Jaiswal M, Divers J, Pop-Busuri R, Feldman EL. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care. 2018;41:e37.
15. TODAY Study Group, Bjornstad P, Nehus E, El Ghormli L, et al. Insulin sensitivity and diabetic kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. Am J Kidney Dis. 2018;71:65-74.
16. SEARCH for Diabetes in Youth Study Group, Kahkoska AR, Isom S, Divers J, et al. The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. J Diabet Complications. 2018;32:1160-1168.
17. Mayer-Davis EJ, Davis C, Saadine J, et al. Diabetic retinopathy in the SEARCH for Diabetes in Youth Cohort: a pilot study. Diabet Med. 2012;29:1148-1152.
18. Tryggstad JB, Willi SM. Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial. J Diabetes Complications. 2015;29:307-312.
19. Committee on Nutrition; Section on Endocrinology; Section on Obesity, Magge SN, Goodman E, Armstrong SC. The metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering. Pediatrics. 2017;140:e20171603.
20. Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl Pediatr. 2017;6:397-407.
21. Shah AS, El Ghormli L, Gidding SS, et al. Prevalence of arterial stiffness in adolescents with type 2 diabetes in the TODAY cohort: relationships to glycemic control and other risk factors. J Diabetes Complications. 2018;32:740-745.
22. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:639-653.
23. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387-397.
24. SEARCH for Diabetes in Youth Study Group, Jaiswal M, Divers J, Urbina EM, et al. Cardiovascular autonomic
neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Cohort Study. *Pediatr Diabetes*. 2018;19:680-689.

25. Reynolds K, Saydah SH, Isom S, et al. Mortality in youth-onset type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth study. *J Diabetes Complications*. 2018;32:545-549.

26. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. *Diabetes Care*. 2018;41:26482668.

27. Zeitler P, Arslanian S, Fu J, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. *Pediatr Diabetes*. 2018;19(suppl 27):28-46.

28. Diabetes Canada Clinical Practice Guidelines Expert Committee, Panagiotopoulos C, Hadjiyannakis S, Henderson M. Type 2 diabetes in children and adolescents. *Can J Diabetes*. 2018;42(suppl 1):S247-S254.

29. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. *Diabetes Care*. 2019;42(suppl 1):S13-S28.

30. Lee JM, Wu E, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? *J Pediatr*. 2011;158:947-952.

31. Nowicka P, Santoro N, Liu H, et al. Utility of Hemoglobin A1c for diagnosing diabetes and prediabetes in obese children and adolescents. *Diabetes Care*. 2011;34:1306-1311.

32. Babar GS, Sherman AK. *Comparison of HbA1c and OGTT for the diagnosis of type-2 diabetes mellitus in overweight children and adolescents*. Denver; 2011.

33. Chan CL, Pyle L, Newnes L, Nadeau KJ, Zeitler PS, Kelsey MM. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. *J Clin Endocrinol Metab*. 2015;100:902-910.

34. Drugs and Therapeutics Committee of the Pediatric Endocrine Society, Kapadia C, Zeitler P. Hemoglobin A1c measurement for the diagnosis of Type 2 diabetes in children. *Int J Pediatr Endocrinol*. 2012;2012:31.

35. Ehelt H, Gauger N, Blumenstock G, et al. Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence. *Pediatr Diabetes*. 2010;11:446-449.

36. Love-Osborne KA, Sheeder J, Svircev A, Chan C, Zeitler P, Nadeau KJ. Use of glycosylated hemoglobin increases diabetes screening for at-risk adolescents in primary care settings. *Pediatr Diabetes*. 2013;14:512-518.

37. Klingensmith GI, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. *Pediatr Diabetes*. 2016;17:266-273.

38. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. *Diabetes*. 2005;54(suppl 2):S52-S61.

39. TODAY Study Group, Klingensmith GI, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. *Diabetes Care*. 2010;33:1970-1975.

40. Arup Laboratories. *Diabetes-Associated Autoantibodies*. 2013. Accessed December 28, 2019. http://ltd.aruplab.com/Tests/Pdf/152

41. Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. *J Clin Endocrinol Metab*. 2013;98:4055-4062.

42. Kanakatti Shankar R, Pihoker C, Dolan LM, et al. Permanent neonatal diabetes mellitus: prevalence and genetic diagnosis in the SEARCH for Diabetes in Youth Study. *Pediatr Diabetes*. 2013;14:174-180.

43. Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. *Curr Diab Rep*. 2018;18:58.

44. McDonald TJ, Shields BM, Lawry J, et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. *Diabetes Care*. 2011;34:1860-1862.

45. Bacon S, Kyiathi MP, Rizvi SR, et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. *Diabet Med*. 2016;33:976-984. doi:10.1111/dme.12992.

46. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA*. 2012;308:2489-2496.

47. Kawahara R, Amemiya T, Yoshino M, Miyamae M, Sasamoto K, Omori Y. Dropout of young non-insulin-dependent diabetics from diabetic care. *Diabetes Res Clin Pract*. 1994;24:181-185.

48. Grinstein G, Muzumdar R, Aponte L, Vuguin P, Saenger P, DiMartino-Nardi J. Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. *Horm Res*. 2003;60:121-126.

49. TODAY Study Group, Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med*. 2012;366:2247-2256.

50. TODAY Study Group. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. *Int J Obes (Lond)*. 2010;34:217-226.

51. Ells LJ, Rees K, Brown T, et al. Correction: interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews. *Int J Obes (Lond)*. 2019;43:1653.

52. Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review. *Int J Endocrinol Metab*. 2019;17:e84353.

53. Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. *Diabetes Spectr*. 2017;30:202-210.

54. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. *N Engl J Med*. 2019;381:637-646.
55. Food and Drug Administration. FDA approves new treatment for pediatric patients with type 2 diabetes. Accessed December 30, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes

56. Victoza.Good Rx. Accessed January 3, 2020. https://www.goodrx.com/victoza/medicare-coverage

57. Pearson S, Kietsiriroje N, Ajjan RA. Oral semaglutide in the management of type 2 diabetes: a report on the evidence to date. Diabetes Metab Syndr Obes. 2019;12:2515-2529.